EUVIMEDEUVIMED entdecken
Metaanalyse

Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling

Yixiao Liu, Ling Xu, Xinrui Wang, Lijuan Wu, Ruifen Cai, Lujin Li, Qingshan Zheng

Expert Review of Clinical Pharmacology · 2023

DOI: 10.1080/17512433.2023.2259300 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Yixiao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine,…. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents, Models, Biological. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Funds of China, Shanghai 3-year Action Plan for Inheritance, Innovation, and Development of traditional Chinese Medicine, China national key research and development program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Further dose optimization is required for patients with moderate-to-severe plaque psoriasis who do not benefit from the approved secukinumab dose regimen. This study aimed to develop an exposure-response model for secukinumab to recommend dose regimens for patients of different body weights. METHODS: We searched the PubMed and Cochrane Library databases for randomized controlled trials using PASI 75 and PASI 90 response rates as primary outcomes. A model-based meta-analysis was developed to quantitatively analyze the distribution of six secukinumab dose regimens in patients weighing 50-120 kg. RESULTS: Sixteen trials involving 6,197 subjects were included in the analysis. The established model accurately described the time-course characteristics of PASI 75 and PASI 90 response rates over 52 weeks. Simulations indicated that maintenance doses could be reduced to 150 mg every 4 weeks and to 150 mg every 3 weeks for patients weighing 50 and 60 kg, respectively. In contrast, maintenance doses of 300 mg every 3 weeks should be selected for patients weighing 120 kg. Patients weighing 70-110 kg remained on approved maintenance doses of 300 mg every 4 weeks. CONCLUSIONS: Based on patient body weights, the exposure-response model recommends efficacious and economical dose regimens for patients with moderate-to-severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsModels, BiologicalHumansDose-Response Relationship, DrugSeverity of Illness IndexRandomized Controlled Trials as TopicBody WeightTreatment Outcome

Stichwörter der Autor:innen

Dose optimizationexposure-response modelmodel-based meta-analysismoderate-to-severe plaque psoriasispsoriasis area and severity indexsecukinumab

Substanzen

Antibodies, Monoclonal, HumanizedsecukinumabDermatologic Agents

Autor:innen und Institutionen

  • Center for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Förderung

  • National Natural Science Funds of China
  • Shanghai 3-year Action Plan for Inheritance, Innovation, and Development of traditional Chinese Medicine
  • China national key research and development program

Zitieren

APA

Liu, Y., Xu, L., Wang, X., Wu, L., Cai, R., Li, L., & Zheng, Q. (2023). Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2259300

Vancouver

Liu Y, Xu L, Wang X, Wu L, Cai R, Li L, et al. Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2259300

BibTeX
@article{Liu2023,
  author = {Liu, Yixiao and Xu, Ling and Wang, Xinrui and Wu, Lijuan and Cai, Ruifen and Li, Lujin and Zheng, Qingshan},
  title = {Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  doi = {10.1080/17512433.2023.2259300}
}
Kostenlos starten →